➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
AstraZeneca
Express Scripts
McKesson
Johnson and Johnson

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

Eszopiclone - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for eszopiclone and what is the scope of freedom to operate?

Eszopiclone is the generic ingredient in two branded drugs marketed by Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Glenmark Generics, Hikma, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Nostrum Labs Inc, Orchid Hlthcare, Sun Pharm, Teva, Wockhardt Ltd, and Sunovion Pharms Inc, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for eszopiclone. Twenty-six suppliers are listed for this compound.

Drug Prices for eszopiclone

See drug prices for eszopiclone

Drug Sales Revenue Trends for eszopiclone

See drug sales revenues for eszopiclone

Recent Clinical Trials for eszopiclone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San DiegoPhase 2
VA Office of Research and DevelopmentPhase 3
VA Office of Research and DevelopmentPhase 4

See all eszopiclone clinical trials

Medical Subject Heading (MeSH) Categories for eszopiclone
Paragraph IV (Patent) Challenges for ESZOPICLONE
Tradename Dosage Ingredient NDA Submissiondate
LUNESTA TABLET;ORAL eszopiclone 021476 2008-12-15

US Patents and Regulatory Information for eszopiclone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm ESZOPICLONE eszopiclone TABLET;ORAL 091103-003 Apr 3, 2013 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Mylan Pharms Inc ESZOPICLONE eszopiclone TABLET;ORAL 091151-002 Mar 26, 2013 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Orchid Hlthcare ESZOPICLONE eszopiclone TABLET;ORAL 091113-002 Jun 10, 2014 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Glenmark Generics ESZOPICLONE eszopiclone TABLET;ORAL 091166-001 Apr 15, 2014 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Nostrum Labs Inc ESZOPICLONE eszopiclone TABLET;ORAL 203087-001 May 8, 2019 DISCN No No   Get Started for $10   Get Started for $10   Get Started for $10
Lupin Ltd ESZOPICLONE eszopiclone TABLET;ORAL 091124-001 Sep 13, 2011 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for eszopiclone

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Johnson and Johnson
Mallinckrodt
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.